The SmartCM is a novel microfluidic biosensor that enables non-invasive, low-cost detection of metastatic cancer through urine analysis. It utilizes nematode movement visualization for quick results within 60 minutes, requiring only 1 mL of sample. Validated in a study with 30 breast cancer patients and 6 healthy controls, the platform demonstrated high sensitivity (87.5%) and significant differences in chemotaxis index values between metastatic and non-metastatic cases. Enhanced for automated, portable use, SmartCM offers potential for remote or home-based cancer testing.
For more info: https://doi.org/10.1016/j.snb.2023.134485
Comentarios